requires a concomitant use of more than one antiepileptic drue4). Valproic acid (VPA) has been found to be effective when used by adding other antiepileptic drugs or used as monotherapy5,6). Therefore, concomitant therapy is often changed to VPA monotherapy, and other antiepileptic drugs are often added to VPA monotherapy.
The serum VPA concentration (G) has been reported to be altered by the concomitant antiepileptic drugs7,8). Thus, it is anxious for the occurrences of adverse reaction caused by the increased G, and for the reduction of main reaction caused by the decreased G. Therefore, evaluating the effects of concomitant antiepileptic drugs on G is important to use the VPA preparations properly, so that many papers have been referred to this point. However, in most of papers, the G measurements were obtained from the patients administrated the conventional preparations of VPA whose absorption rates were relatively rapiell) and the number of measurements in each patient was different12). Accordingly, the G values would vary greatly and, consequently, there seemed to be little consistency in the effects of concomitant antiepileptic drugs on G. On the contrary, the sustainedrelease preparations of VPA (VPA-R) show a narrow G range in the oral administration once or twice a day13). Therefore, we collected the data from the epileptic patients administrated VPA-R and studied to obtain a quantitative expression which could provide the alteration of G in changing the combination of concomitant antiepileptic drugs with VPA-R.
Method
Data were collected from the epileptic patients, who were treated with repetitive oral administration of VPA-R (Selenica-R(R) granules, Nikken Chemicals Co., LTD. Tokyo Japan, Depakene-R(R) tablets, Kyowa Hakko Kogyo, Tokyo, Japan) at both Kagawa Medical University Hospital and Kurashiki Central Hospital from April 1995 to September 1996. The patients of abnormal findings on hepatic and renal functions were excluded. Blood samples were obtained 2 to 3 hours after last dosing in outpatients and 2 to 15 hours in inpatients. Ct was measured in duplicate by FPIA method (TDX(R) or FLX(R) system, DAINABOT, Tokyo Japan) in both hospitals.
When there were several measurements for G in one patient at the same prescribed drugs during the investigation period, the average value was used as a representative one. The age, body weight, heightand the VPA daily dose were treated similarly. When there were several varieties of prescribed drugs in one patient, the count was taken as the number of patients.
The total numbers of patients administrated VPA-R alone and coadministrated other antiepileptic drugs with VPA-R were 233 and 114, respectively. The total of 347 cases were used for analysis.
Data analysis was performed by utilizing the statistical packages, NAP (ver.4)14). Table 1 shows the characteristics of the patients administrated VPA-R in each hospital. Kagawa Medical University Hospital abounded in pediatric patients and in the patients coadministrated other antiepileptic drugs with VPA-R. Accordingly, significant differences in the age (AGE), body weight (W), height (H) and the VPA-R therapy were observed between two hospitals. On the other hand, no significant differences in G, the VPA daily dose (D) and the number of drugs coadministrated were observed.
Results

Characteristics of the Patients
By assembling the data of two hospitals together, we could collect many data in a wide range of age.
Effects of Concomitant Antiepileptic Drugs on C,
(1) C, for VPA-R Alone In previous paperth) we reported that G could be satisfactorily correlated to only one variable of the VPA daily dose per modified body weight, and could be expressed as eq. (1) In Fig. 1 , solid curve 1 and broken curve 2 represent the regression curves calculated from eq.
(1) and eq. (2), respectively. Both curves were in fair agreement with each other in the extent of adopted X values. Namely, the sample standard deviations from regression curves were calculated We assumed that eq.(2) could be adapted to express C for the case of coadministration of another antiepileptic drug with VPA-R. Converting both members of eq.(2) into common logarithms, y =a+bx (3) where, y= log C1, x =logX, a =logA and b =B. We paid no regard to the dose of concomitant antiepileptic drug in this assumption. Fig. 2 shows the regression lines with respect to logC vs. logX for VPA-R alone and for another concomitant antiepileptic drug, such as PB, CBZ, PHT and ZNS, with VPA-R. The regression line and the sample standard deviation from regression line (Sr) are shown in Table 2 . The number of patients coadministrated PRM, CZP or ETS with VPA-R was not enough to calculate the regression line.
As shown in Because the plots scattered widely (see Sy values in Table 2 ), a statistical method18) was employed to compare the regression line for VPA-R alone with another. The results are shown in Ta- where R is a coefficient representing the effect of each concomitant antiepileptic drug on G at VPA-R alone, i.e., AV. Hereinafter, R, is called an alteration ratio. The subscript i represents the concomitant drug, and i 1, 2, ,7 corresponds to PRM, PB, CBZ, PHT, ZNS, CZP, ETS, respectively. z, is 1 or 0 when drug i is coadministrated or not.
In eq.(4), C is expressed with the assumption that the effects of concomitant antiepileptic drugs on G are independent and multiplicative with each other. And no regard was paid to the doses of concomitant antiepileptic drugs in this model.
Converting both members of eq.(4) into common logarithms,
where, y = logG, a = logA , b=B, x=logX , r,= logRi.
The 233 patients were administrated VPA-R alone. The 87, 21 and 6 patients were coadministrated one, two and three different antiepileptic drugs, respectively ( Table 1 ). The total of 347 cases were used in eq.(5) for a multiple regression analysis. Table 3 shows the results. There were 3 pa- The multiple regression analysis without variable selection estimated r5 for ZNS at 0.008. This value comes to 1.019 in R. The standard deviation of r5 was 0.029 and practically equal to those of PB, CBZ and PHT. Thus, ZNS would be said to have no effect on G. PRM, CZP, ETS altered G to 1.138, 0.952 and 1.050 times, respectively. Nevertheless, the multiple regression analysis with variable selection did not select them as the influencing drug on G. Because the number of the patients administrated these drugs was not enough and the data scattered widely, their effects on C were considered not to be detected.
Discussion
To investigate the effects of concomitant antiepileptic drugs on C. it is preferred to clarify the relationship between the daily dose and G for the patients administrated VPA-R alone. Some papers mentioned the nonlinearity between the daily dose and G19,20). Eq.(1), proposed in our previous paper, represented this relationship fairly15). As shown in Fig. 1 , the convenient eq. This portion is not equal torin eq.(2), but nearly corresponds toV. Eq.(1) should be used primarily for the analysis of the effects of concomitant antiepileptic drugs on G. But the standard deviations of the estimated parameter values in eq.(1) even for VPA-alone group15) were too large. In concomitant therapy, the deviations would be more large and the confidence of parameters would be lost.
Then, eq.(2) expressed by two parameters was used for the analysis.
Eq.(2) was transformed as a linear eq.(3) by converting both members into common logarithms.
By comparing the regression line for VPA-R alone with that for another concomitant antiepileptic drugs such as PB, CBZ, PHT and ZNS, it was revealed that the slopes of all lines were not different, but neither of the heights for PB, CBZ and PHT were not equal to the height for VPA-R alone (Fig. 2, Table 2 ). The former result agreed with the reports that these drugs did not affect the plasma protein binding of VPA21 '22) . The latter one indicated that A in eq. (2) was altered by such concomitant drugs. Thus, G would be affected at each definite ratio by these antiepileptic drugs and the alteration of elimination rate and bioavailability would reflect on R value.
It was postulated that, when more than two sorts of antiepileptic drugs were coadministrated, the effects of these drugs on G were independent with each other. More precise and great many patients data may be needed to do a detail investigation about the interactions between antiepileptic drugs. Sy for VPA-R alone in the simple regression analysis was 0.139 (Table 2) , and Sy for all cases including one to three concomitant antiepileptic drugs was 0.135 (Table 3, with variable As this model can analyze all cases inclusively, the reliabilities of parameters estimated will be increased.
The multiple regression analysis revealed that PB, CBZ and PHT lowered G to 0.879, 0.812 and 0.833 times, respectively (Table 3) . Our results agreed with the reports that PB, CBZ and PHT lowered G in a concomitant use7 '8'11) . On the contrary, ZNS did not affect G. The results of R <1 indicates that the concomitant antiepileptic drugs raises mainly the value of elimination rate constant.
These findings would be led by the inducing actions of drug-metabolizing enzymes possessed in these antiepileptic drugs23-25). On the other hand, it is suggested that ZNS has little effect on G because of its little inducing and inhibitory effect on the enzymesm. Additionally, G was reported not to be affected by ZNS27). Thus, our results coincided with those reported by previous investigators.
PRM, CZP and ETS could not be clarified whether they affected C or not, because the number of patients coadministrated were not enough and the data were scattered. Nevertheless, PRM is anticipated to lower G by its metabolized PB.
When the concomitant antiepileptic drugs such as PB, CBZ, and PHT are changed in the same patient, the alteration of G can be estimated from eq.(4) by using the values of R2, R3 and R4 ( Table 3 ). An example will be shown below. ex. In the case of discontinuation of CBZ from the concomitant therapy of CBZ and PHT with VPA-R. When G (3,4) means G at the concomitant therapy of CBZ and PHT with VPA-R and G(4) means G at PHT with VPA-R, Ct(3,4) and G(4) can be written as, where X is the VPA daily dose (D) per modified body weight (WM). From eqs. (6) and (7), Thus, C, is expected to be increased to 1.23 times by discontinuation of CBZ.
The VPA daily dose to maintain C can be estimated by putting C(3,4) Ct(4). Then, AXE' X R3 X R4 =AX(4)B X R4 where X(4) is D(4)/WM and D(4) is the VPA daily dose after discontinuation of CBZ. Substituting D/ WM and D4/WM in X and X(4) respectively, and rearranging, As D (3,4) is the VPA-R daily dose before discontinuation of CBZ, the VPA daily dose after discontinuation should be decreased to 0.75 times to maintain the same level of G.
To evaluate the values of R obtained in this study, the measured and estimated values of G were compared between the cases where the prescribed drugs were changed in the same patient. For PB, (Table 3) . For PRM, ZNS, CZP and ETS, R was postulated to be 1. Fig. 3 shows the plots of estimated C versus measured G. Both values seem to be in good agreement. The mean absolute error (MAE) was calculated as 23.0%, by the following equation.
In the VPA therapy, the therapeutic drug monitoring will be more worthy because VPA-R became available in clinical use. Therefore, the increase in the patient is expected, who alters his treatment of VPA-R to mono/concomitant therapy to each other. Our alteration ratios presented in this study will be useful indicatdrs for the estimation of G in the case of addition or discontinuation of concomitant antiepileptic drugs and for the advices in the treatment of VPA-R for epileptic patients. (n: number of sets compared)
